No Data
HUMAN HEALTH (01419.HK) plans to acquire 75% equity in Youde Dental Clinic for 38.85 million Hong Kong dollars.
On January 3, according to a announcement from HUMAN HEALTH (01419.HK), Rank Best (a wholly-owned subsidiary) entered into a sale and purchase agreement with Dr. Zhang Yulong, in which Rank Best conditionally agreed to acquire, and the seller conditionally agreed to sell 75% of the issued share capital of the target company Youde Dental Clinic Limited for a price of 38.85 million HKD (subject to adjustments). The target company is ultimately held by Dr. Zhang through the seller and is mainly engaged in the Operation of dental clinics to provide dental services. Upon completion, Rank Best will hold.
Express News | Human Health Holdings Ltd - Unit to Buy 75% of Total Issued Share Capital of Monarch Medical Services for HK$38.9 Mln
Human Health (01419): Xian Jiatian resigns as an independent non-executive director.
Human Health (01419) announced that Mr. Kam Ka-tim (Mr. Kam) has retired from the board of directors after serving for more than 8 years based on rotation.
Human Health (01419.HK): Chen Xiwen appointed as the chairman of the audit committee.
On December 2, Gronghui reported that human health (01419.HK) announced that due to the rotation of duties, Xian Jia Tian has served on the board of directors for over 8 years and will rotate out at the shareholder annual meeting. Although Mr. Xian is eligible for reappointment, he will not participate in the reelection at the shareholder annual meeting. Mr. Xian's resignation will take effect at the end of the shareholder annual meeting. Chen Xiwen has been appointed as the chairman of the audit committee, effective at the end of the shareholder annual meeting.
HUMAN HEALTH: 2024 Annual Report
human health (01419.HK) fiscal year 2024 earnings approximately 0.591 billion Hong Kong dollars, a year-on-year decrease of approximately 41.0%.
Gelonghui September 25th | Human Health (01419.HK) announced that the group's income in the 2024 fiscal year is approximately 590.8 million Hong Kong dollars, a decrease of about 41.0% from the 2023 fiscal year. This decrease is mainly due to a decrease in revenue of about 509.0 million Hong Kong dollars generated by services related to the 2019 coronavirus disease prevention, testing, vaccine administration, and outreach. Excluding the revenue generated by these services, the group's income increased by about 19.9% compared to the 2023 fiscal year. The company's attributable profit is approximately 24.2 million Hong Kong dollars, a decrease of about 156.6 million Hong Kong dollars or 86.6% from the 2023 fiscal year. Excluding non-financial assets.
